The 2nd Meeting of National Control Laboratories for Vaccines and Biologicals in the Western Pacific.
10.24171/j.phrp.2018.9.3.10
- Author:
Hokyung OH
1
;
Jinho SHIN
;
Chung Keel LEE
;
Masaki OCHIAI
;
Kiyoko NOJIMA
;
Chang Kweng LIM
;
Sanj RAUT
;
Irene LISOVSKY
;
Stella WILLIAMS
;
Ki Young YOO
;
Dong Yeop SHIN
;
Manabu ATO
;
Qiang YE
;
Kiwon HAN
;
Chulhyun LEE
;
Naery LEE
;
Ji Young HONG
;
Kikyung JUNG
;
Pham VAN HUNG
;
Jayoung JEONG
Author Information
1. National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Korea. 0jjy@korea.kr
- Publication Type:Note
- Keywords:
quality control;
immunoglobulin;
blood coagulation factors;
Japanese encephalitis
- MeSH:
Blood Coagulation Factors;
Canada;
China;
Complement System Proteins;
Encephalitis, Japanese;
Factor VIII;
Immunoglobulins;
Japan;
Korea;
Malaysia;
Quality Control;
Republic of Korea;
Vaccine Potency;
Vaccines*;
Vietnam;
World Health Organization
- From:
Osong Public Health and Research Perspectives
2018;9(3):133-139
- CountryRepublic of Korea
- Language:English
-
Abstract:
The Second Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific, was jointly organized by the National Institute of Food and Drug Safety Evaluation of the Ministry of Food and Drug Safety in the Republic of Korea, and by the World Health Organization Regional Office for the Western Pacific. In the National Lot Release Systems session countries including Canada, China, Japan, Malaysia, Vietnam, and the Republic of Korea, all shared information on their current Lot Release Systems, including current practices and developments in risk-based official lot release of vaccines. In the session on Quality Control of Blood Products, experts from the National Institute for Biological Standards and Control shared quality control and research results for; blood coagulation factor VIII products, and the measurement of procoagulant activity in immunoglobulin products. Representatives from Japan proposed a regional collaborative study to test aggregated immunoglobulin free from complement activity. A cell-based Japanese encephalitis vaccine potency assay was proposed by representatives from Korea and they also called for voluntary participation of other National Control Laboratories in a collaborative study, on the first Korean Gloydius anti-venom standard. Participants agreed in general to continue communicating, and coordinate presentation of the study results.
